SI9300468A - Injectable composition for the sustained release of biologically active compounds - Google Patents

Injectable composition for the sustained release of biologically active compounds Download PDF

Info

Publication number
SI9300468A
SI9300468A SI9300468A SI9300468A SI9300468A SI 9300468 A SI9300468 A SI 9300468A SI 9300468 A SI9300468 A SI 9300468A SI 9300468 A SI9300468 A SI 9300468A SI 9300468 A SI9300468 A SI 9300468A
Authority
SI
Slovenia
Prior art keywords
solvent
lecithin
composition according
additives
composition
Prior art date
Application number
SI9300468A
Other languages
English (en)
Slovenian (sl)
Inventor
Ralph Tarantino
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SI9300468A publication Critical patent/SI9300468A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
SI9300468A 1992-10-14 1993-09-08 Injectable composition for the sustained release of biologically active compounds SI9300468A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96075292A 1992-10-14 1992-10-14

Publications (1)

Publication Number Publication Date
SI9300468A true SI9300468A (en) 1994-06-30

Family

ID=25503572

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300468A SI9300468A (en) 1992-10-14 1993-09-08 Injectable composition for the sustained release of biologically active compounds

Country Status (19)

Country Link
US (1) US5863549A (is)
EP (1) EP0620740B1 (is)
JP (1) JP2613750B2 (is)
CN (1) CN1090509A (is)
AT (1) ATE180976T1 (is)
AU (1) AU672441B2 (is)
CA (1) CA2125784A1 (is)
DE (1) DE69325256T2 (is)
ES (1) ES2133413T3 (is)
IL (1) IL107207A0 (is)
IS (1) IS4083A (is)
LV (1) LV10180A (is)
MX (1) MX9306239A (is)
NZ (1) NZ256413A (is)
RU (1) RU94033520A (is)
SI (1) SI9300468A (is)
UY (1) UY23665A1 (is)
WO (1) WO1994008623A1 (is)
ZA (1) ZA937459B (is)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US6379631B1 (en) 1996-06-28 2002-04-30 Johnson & Johnson Medical, Inc. Instrument sterilization container formed of a liquid crystal polymer
US6264902B1 (en) 1996-06-28 2001-07-24 Johnson & Johnson Medical, Inc. Instrument sterilization container having an improved latching mechanism
SK20012000A3 (sk) * 1998-06-29 2001-08-06 Pharmaceuticals Applications Asociates, Llc Transdermálny prostriedok na zmiernenie bolesti
CA2336879C (en) * 1998-07-20 2010-06-01 Peptech Limited Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients
AU755443C (en) * 1998-07-20 2006-08-17 Virbac (Australia) Pty Limited Bioimplant formulation
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
US6979459B1 (en) 2000-04-06 2005-12-27 Perricone Nicholas V Treatment of skin damage using polyenylphosphatidycholine
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
US6932963B2 (en) 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
US20020106406A1 (en) * 2000-12-08 2002-08-08 Mchugh Anthony J. Crystallizable/non-crystallizable polymer composites
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
BR0308137A (pt) 2002-03-04 2005-01-04 Sod Conseils Rech Applic Formulações de droga de liberação constante contendo um peptìdeo veìculo
JP2005528352A (ja) 2002-03-12 2005-09-22 エチファルム 生体活性物質の持続的放出に用いるためのゲル化特性を有する組成物
KR100906547B1 (ko) 2002-03-12 2009-07-07 에띠빠흠 생활성 물질의 지속적 전달을 위한 겔화 특성을 갖는 조성물
US20040025791A1 (en) * 2002-08-09 2004-02-12 Applied Materials, Inc. Etch chamber with dual frequency biasing sources and a single frequency plasma generating source
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
JP2008502690A (ja) * 2004-06-15 2008-01-31 アンドリュー シァン チェン， リン脂質組成物ならびにその調製方法および使用方法
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
JP2008539260A (ja) * 2005-04-25 2008-11-13 アムジエン・インコーポレーテツド ポロゲンを含む生分解性プチド徐放性組成物
US7695633B2 (en) * 2005-10-18 2010-04-13 Applied Materials, Inc. Independent control of ion density, ion energy distribution and ion dissociation in a plasma reactor
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
PL1787658T3 (pl) 2005-11-10 2012-08-31 Italfarmaco Spa Formulacje o przedłużonym uwalnianiu analogów somatostatyny będących inhibitorami hormonu wzrostu
US8017159B2 (en) * 2005-11-16 2011-09-13 Idexx Laboratories, Inc. Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same
US20070246162A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Plasma reactor apparatus with an inductive plasma source and a VHF capacitively coupled plasma source with variable frequency
US20070245961A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Dual plasma source process using a variable frequency capacitively coupled source for controlling plasma ion dissociation
US20070245960A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion density
US7645357B2 (en) * 2006-04-24 2010-01-12 Applied Materials, Inc. Plasma reactor apparatus with a VHF capacitively coupled plasma source of variable frequency
US20070246443A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Process using combined capacitively and inductively coupled plasma process for controlling plasma ion dissociation
US7727413B2 (en) * 2006-04-24 2010-06-01 Applied Materials, Inc. Dual plasma source process using a variable frequency capacitively coupled source to control plasma ion density
US20070246163A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Plasma reactor apparatus with independent capacitive and inductive plasma sources
US20070245958A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Dual plasma source process using a variable frequency capacitively coupled source for controlling ion radial distribution
US20070246161A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Plasma reactor apparatus with a toroidal plasma source and a VHF capacitively coupled plasma source with variable frequency
US7780864B2 (en) * 2006-04-24 2010-08-24 Applied Materials, Inc. Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion radial distribution
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
CN101827613A (zh) 2007-09-27 2010-09-08 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
WO2009114959A1 (zh) * 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 可注射用缓释药物制剂及其制备方法
EP2296696B1 (en) * 2008-06-05 2014-08-27 ImmunoVaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
BRPI1010874A8 (pt) * 2009-05-01 2018-01-02 Ferring Bv composição para o tratamento de câncer de próstata
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
KR101793101B1 (ko) 2010-08-20 2017-11-02 닥터 레디스 래보러토리즈 에스에이 인지질 데포
NZ608406A (en) 2010-10-22 2015-06-26 Reddy’S Lab Inc Dr Use of storage stable viscous phospholipid depot to treat wounds
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
WO2012055903A1 (en) 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
KR20140041686A (ko) * 2011-06-09 2014-04-04 아밀린 파마슈티칼스, 엘엘씨. 겔 조성물
AU2012321022B2 (en) 2011-10-06 2017-03-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
CA2871821C (en) 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
TWI580443B (zh) 2012-06-01 2017-05-01 菲瑞茵公司 地蓋瑞利（ｄｅｇａｒｅｌｉｘ）之製備技術
KR102227966B1 (ko) * 2019-06-26 2021-03-16 주식회사 엠이티라이프사이언스 비활성 폴리펩타이드 ｔｒｐ의 약제학적 제형

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4252793A (en) * 1979-06-18 1981-02-24 American Lecithin Company Injectable lecithin preparation
US4297353A (en) * 1980-08-04 1981-10-27 Sandoz, Inc. Non-irritating injectable dosage forms
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
FR2562421B1 (fr) * 1984-04-09 1989-02-17 Sandoz Sa Perfectionnements a la therapie par l'interleukine
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
US5084269A (en) * 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
CH681427A5 (is) * 1987-07-01 1993-03-31 Zambon Spa
JP2643217B2 (ja) * 1988-01-22 1997-08-20 エーザイ株式会社 脂溶性物質水性液
US5124151A (en) * 1990-08-07 1992-06-23 Mediventures Inc. Drug delivery by injection with thermo-irreversible gels
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5505877A (en) * 1991-10-15 1996-04-09 Krivohlavek; Dennis Making multiple phase emulsion or gel
DE4201527A1 (de) * 1992-01-21 1993-07-22 Knoll Ag Lecithinhaltige loesungen mit levemopamil
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5660854A (en) * 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material

Also Published As

Publication number Publication date
RU94033520A (ru) 1996-11-10
UY23665A1 (es) 1994-04-06
CN1090509A (zh) 1994-08-10
JPH06511263A (ja) 1994-12-15
MX9306239A (es) 1994-06-30
IL107207A0 (en) 1994-01-25
IS4083A (is) 1994-04-15
ZA937459B (en) 1994-04-14
ES2133413T3 (es) 1999-09-16
CA2125784A1 (en) 1994-04-28
AU672441B2 (en) 1996-10-03
AU5111093A (en) 1994-05-09
US5863549A (en) 1999-01-26
WO1994008623A1 (en) 1994-04-28
DE69325256T2 (de) 1999-12-16
NZ256413A (en) 1996-07-26
LV10180A (lv) 1994-10-20
ATE180976T1 (de) 1999-06-15
EP0620740A1 (en) 1994-10-26
JP2613750B2 (ja) 1997-05-28
DE69325256D1 (de) 1999-07-15
EP0620740B1 (en) 1999-06-09

Similar Documents

Publication Publication Date Title
SI9300468A (en) Injectable composition for the sustained release of biologically active compounds
JP5171262B2 (ja) ソマトスタチン類似体製剤
JP5107725B2 (ja) ＧｎＲＨ類似体製剤
US6719992B2 (en) Non-aqueous surfactant-containing formulations for extended release of somatotropin
EP0220153B1 (en) A nutritive emulsion having oxygen-transporting properties, and process for its preparation
SK16552002A3 (sk) Stála, biologicky zlúčiteľná, dobre znášateľná mikroemulzia voda v oleji a jej použitie
JP2004285079A (ja) 徐放性タンパク質製剤
CN107205920B (zh) 可注射丁丙诺啡制剂
TR201806985T4 (tr) GnRH analoglarının ve bunu içeren farmasötik bileşimin sürekli salım lipit ön konsantresi.
US20220125888A1 (en) Sustained-release lipid preformulation and pharmaceutical composition for sustained-release injection in form of lipid solution containing same
US4775659A (en) Injectable semi-solid formulations
EP0351651B1 (en) Insulin preparation
HUT75252A (en) Oral pharmaceutical compositions
JP3848537B2 (ja) ドラメクチン製剤
KR20200135280A (ko) 지속 방출 펩티드 제형
KR100329336B1 (ko) 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형
US9956164B2 (en) Veterinary pharmaceutical composition and use thereof
KR20020067781A (ko) 구충용 이버멕틴 주사제 조성물 및 그 제조방법
EP0427998A2 (en) A pharmaceutical composition for rectal administration of calcitonin